Dimethyl fumarate for treating relapsing multiple sclerosis

Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate’s protective effect in EAE

(2014) Hui Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

Cerebellar manifestation of PML under fumarate and after efalizumab treatment of psoriasis

(2014) Muriel Stoppe et al.   JOURNAL OF NEUROLOGY

Multiple sclerosis: Prospects and promise

(2013) Stephen L. Hauser et al.   ANNALS OF NEUROLOGY

Quality of life outcomes with BG-12 (dimethyl fumarate) in patients with relapsing–remitting multiple sclerosis: The DEFINE study

(2013) Ludwig Kappos et al.   Multiple Sclerosis Journal

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis

(2013) Markus Axelsson et al.   Multiple Sclerosis Journal

PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy

(2013) Bob W. van Oosten et al.   NEW ENGLAND JOURNAL OF MEDICINE

Manufacturer's Response to Case Reports of PML

(2013) Marianne T. Sweetser et al.   NEW ENGLAND JOURNAL OF MEDICINE

PML in a Patient Treated with Fumaric Acid

(2013) Ummehan Ermis et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer

(2013) Emilia Kansanen et al.   Redox Biology

Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: Evolving role of biologic therapies

(2012) Eamonn S. Molloy et al.   ARTHRITIS AND RHEUMATISM

Dimethyl Fumarate Inhibits Dendritic Cell Maturation via Nuclear Factor κB (NF-κB) and Extracellular Signal-regulated Kinase 1 and 2 (ERK1/2) and Mitogen Stress-activated Kinase 1 (MSK1) Signaling

(2012) Haiyan Peng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies

(2012) A. Bellizzi et al.   JOURNAL OF NEUROVIROLOGY

The initiation and prevention of multiple sclerosis

(2012) Alberto Ascherio et al.   Nature Reviews Neurology

The “Poison Chair” Treatment for Multiple Sclerosis

(2012) Allan H. Ropper   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy

(2012) Gary Bloomgren et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Fumaric acid and its esters: An emerging treatment for multiple sclerosis with antioxidative mechanism of action

(2011) R. Gold et al.   CLINICAL IMMUNOLOGY

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study

(2011) Bhupendra Khatri et al.   LANCET NEUROLOGY

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Dimethylfumarate inhibits microglial and astrocytic inflammation by suppressing the synthesis of nitric oxide, IL-1β, TNF-α and IL-6 in an in-vitro model of brain inflammation

(2010) Henrik Wilms et al.   Journal of Neuroinflammation

Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases

(2010) David B Clifford et al.   LANCET NEUROLOGY

Fumaric acid diesters deprive cultured primary astrocytes rapidly of glutathione

(2010) Maike M. Schmidt et al.   NEUROCHEMISTRY INTERNATIONAL

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chemotherapeutics in the treatment of multiple sclerosis

(2010) Bernd C. Kieseier et al.   Therapeutic Advances in Neurological Disorders

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis

(2009) D. Moharregh-Khiabani et al.   Current Neuropharmacology

The Nrf2-Antioxidant Response Element Signaling Pathway and Its Activation by Oxidative Stress

(2009) Truyen Nguyen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

250 μg or 500 μg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

(2009) Paul O'Connor et al.   LANCET NEUROLOGY

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

(2008) Daniel D Mikol et al.   LANCET NEUROLOGY

FOUR NEW CASES OF THERAPY-RELATED ACUTE PROMYELOCYTIC LEUKEMIA AFTER MITOXANTRONE

(2008) I. Bosca et al.   NEUROLOGY